| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | Human mesothelioma cells from patients with malignant epithelial mesothelioma were used as the immunogen for the Mesothelial Cell antibody. |
| Isotype | |
| Product Type | |
| Reactivity | |
| Storage | |
| Target |
Overview
Mesothelial Cell Antibody is an antibody targeting Mesothelial. Host: Mouse. Monoclonal. Clone: HBME-1. Format: Bioreactor concentrate. Applications: IF, IHC-P.
Key elements and design rationale
- Target: Mesothelial.
- Immunogen: Human mesothelioma cells from patients with malignant epithelial mesothelioma were used as the immunogen for the Mesoth….
- Species reactivity: Human.
- Localization: Cell membrane.
- Conjugate: Unconjugated (no label listed).
Biological background (from provided description)
This antibody reacts with an unknown antigen on microvilli of mesothelioma cells.
Common research applications
- IHC: tissue distribution assessment; interpret with matched controls.
- IF/ICC: subcellular localization imaging with proper background controls.
Notes for experimental interpretation
- Account for isoforms, paralogs, and post-translational modifications when interpreting signal.
- Support specificity with biological controls (e.g., KO/KD where available) and technical controls (e.g., secondary-only/isotype).
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
